Joseph Papa’s next office in a pharma industry executive suite is at Emergent BioSolutions, Inc., the Maryland firm manufacturing Narcan, the first OTC naloxone product available in the US after becoming synonymous with opioid overdose emergency treatment.
OTC Naloxone Pioneer Emergent BioSolutions Puts Papa At Helm As It Navigates Strategy Shift
Papa Takes OTC Naloxone Pioneer Emergent BioSolutions Helm As It Navigates Strategy Shift
Like his previous move, Papa joins a pharma firm making a significant organizational shift to cut costs and increase revenues after extended period of higher spending and slowing income.
More from Leadership
More from HBW Insight
• By
The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.
• By
Fragrance Creators Association will push the Trump Administration to exclude from tariffs fragrance materials that cannot be produced or cultivated domestically, while both FCA and the Personal Care Products Council will continue to promote the economic benefits of their respective industries.
• By
Agreement with Seoul-based health and wellness player TopHealth will see the roll out of ProBiotix' cholesterol-lowering probiotics in South Korea.